Decoding the Future: Leveraging Biomarkers in Antigen-Specific Immunotherapy for Type 1 Diabetes

Time: 12:15 pm
day: Conference Day One


  • Discussing immunological and genetic findings from clinical trials evaluating the antigenspecific immunotherapy Diamyd (rhGAD65/alum)
  • Highlighting the significance of HLA testing, exploring HLA haplotype frequencies and their relevance for personalized immunotherapy approaches and patient selection
  • Designing the Phase 3 trial DIAGNODE-3 from a biomarker perspective, including the collection of data for future potential personalization of the investigational therapy